Androgens & Anti-Androgens Flashcards
Androgens
19C compound derived from cholesterol
Androgenic Precursors
- DHEA: dehydroepiandrosterone
- Androstnedione
- inactive; must be converted
DHEA: dehydroepiandrosterone
- androgenic precursor
- adrenal cortex; testes
- inactive
Androstenedione
- androgenic precursor
- adrenal cortex; testes
- inactive
Androgens
Name two
- Testosterone
- DHT: dihydrotestosterone
Testosterone
- testes
- MOST ABUNDANT
DHT
Dihydrotestosterone
- androgen target cells and tissues
- – paracrine/autocrine manner
- MOST POTENT natural androgen
Adult male [testosterone]
[T]testes 100x > [T]serum
17-B-hydroxysteroid dehydrogenase (17B-HSD)
- converts DHEA and androstenedione to testosterone
- expressed in testicular leydig cells
5-a-reductase
testosterone -> DHT
- androgen-responsive target tissues
- most DHT production occurs outside the testes
How much testosterone is produced in the adrenal cortex?
<5%
Aromatase (CYP19)
androgens are OBLIGATE precursors to estrone and estradiol
- more fat = more estradiol
Androgen Receptor: males express
only 1
Regulation of Androgen Production from Testes
- Hypothalamus = pulse generator
- – GnRH: hypothalamus -> pituitary (+)
- FSH: pituitary -> testes/seminiferous tubules (+)
- LH: pituitary -> testes/Leydig cells
- – C -> T
- Testosterone: testes -> pituitary & hypothalamus (-)
Testosterone secreted by Leydig cells play critical role in ____
spermatogenesis
Androgen Signaling Pathways
1) ligand binding triggers loss of heat shock proteins
2) nuclear localization
3) coactivators lead to transcription
T -> DHT
5-a-reductase
- DHT binds 5x more tightly to AR
T -> Estradiol
Aromatase
Androgen Actions
Developmental (males)
- Embryonic/Fetal: masculinize internal and external male genitalia
- Puberty
- – regulate growth and development of male reproductive tract
- – regulate linear growth and physical development
- – imprint male behavior and libido
Androgen Actions
Metabolic Adult Males
Bone
- maintains and strengthens bone mass by increasing osteoblast proliferation and decreasing bone resorption by osteoclasts
Androgen Actions
Metabolic Adult Males
Muscle
- increases protein synthesis
- increases size and length of muscle fibers
- increases muscle mass
Androgen Actions
Metabolic Adult Males
Blood
- increases erythropoietin
- increases maturation of erythrocytes
- increases number of red blood cells
Androgen Actions
Metabolic Adult Males
skin
increases sebum production in sebaceous glands
Androgen Actions
Metabolic Adult Males
Liver
- increases LDL
- decreases HDL
- implications for CV function
Androgen Actions
Metabolic Adult Males
Reproduction
- maintains and regulates the male reproductive tract
Androgen Actions
Metabolic Adult
Females
- normal patterns of body hair growth, muscle growth, libido
- maintain bone density
Breakdown of Creation of Androgens in Females
50% adrenal cortex
50% ovaries
Therapeutic uses of ANdrogens
- Male Hypogonadism
- Andropause
Male Hypogonadism
- defect in testicular function that leads to testosterone deficiency
Andropause
- male senescence; late onset hypogonadism; LOH
Androgen Replacement Therapy for Andropause
CONTROVERSIAL
Therapeutic Androgenic Drug Preparations
- when oral, rapidly degraded by liver, limiting oral bioavailability
Effective androgen therapy requires:
1) testosterone in a slow continuously absorbed form
2) chemically modified testosterone derivatives that bypass metabolism in the body
3 types of T modifications
1) Type A: esterification of C17 hydroxyl group
2) Type B: alkylation of the C17a position
3) Type C: modifications of the A, B, or C rings
Type B+C= very effective
Type A Modifications
Esterification of C17 Hydroxyl Group
- make more hydrophobic/lipophilic
- allows slow and continuous release into the bloodstream
- the longer the ester carbon chain, the more prolonged the action
- T esters must be hydrolyzed back into free testosterone to become biologically active
Testosterone undecanoate
- Type A Modification
- lasts the longest because longest C chain
- intramuscular injection every 6-8 weeks
Type B Modifications
Alkylation of the C17a position
- increases oral availability; VERY TOXIC to liver
- inhibits hepatic catabolism = higher bioavailability
- Drawback: prolonged use is associated with liver toxicity
Methyltestosterone
Type B Modification
Type C ad B Modifications
Modification of A/B/C rings AND C17 a-alkylation
MOST POTENT
- enhances the androgenic potency
- usually found in combination with C17 a-methylation, thus increasing bioavailability
- can increase affinity for receptor
OR - can make not a substrate for aromatase, causing it to hang around longer
Oxandrolone
C/B modification
- does not aromatize
Stanozolol
B/C modification
- does not aromatize
Fluoxymesterone
B/C modification
- 5x potency of T
- does not aromatize
Danazol
B/C modification
- does not aromatize
Anabolic Steroid Misnomer
there are no purely anabolic steroids
- initial studies done on animals
Side Effects of Androgenic Drugs
- prostate enlargement/malignancy
- dyslipidemia
- severe acne
- thinning of hair on scalp/baldness
- fluid retention/edema
- high BP
- liver damage (esp C17 a-alkylated derivatives)
- erythrocytosis
Anti-Androgens
2 Classes
- drugs that block endogenous androgen production
- drugs that block the androgen receptor
Therapeutic uses of Anti-Androgens
- prostate cancer
- benign prostate hyperplasia (BPH)
- male-patter hair loss
- hirsutism (females)
Prostate Cancer
- most commonly diagnosed malignancy
- initially dependent on androgens for growth and survival
Huggins and Hodges Key Findings
- reduction of testosterone levels by surgical orchiectomy (castration) or by injection of estrogens results in regression of prostate cancer
- exogenous testosterone injections results in progression of prostate cancer
Drugs that Block Endogenous Androgen Production
3 Classes
1) Inhibitors of Hypothalamic-Pituitary-Testes Signaling
2) Inhibitors of Androgen Biosynthesis
3) Inhibitors of DHT Biosynthesis
1) Inhibitors of Hypothalamic-Pituitary-Testes Signaling
- GnRH receptor agonists and antagonists
- estrogenic treatment
Ketoconazole
2) Inhibitors of Androgen Biosynthesis
First Generator
- prevents oxidation
- – sterically occludes anything from getting into active site
- potent NONSELECTIVE inhibitor
- inhibits 3 out of 4 enzymes involved in testosterone biosynthesis
- if female took it would also inhibit estrogen
- also inhibits CYP3A4: could interfere with drug metabolism
Finesteride
3) Inhibitors of DHT Biosynthesis
- 90% DHT reduction in prostate
- can act as androgen receptor antagonist
Duasteride
3) Inhibitors of DHT Biosynthesis
- 99% DHT reduction in the prostate
- prevents most hairloss
Abiraterone
2) Inhibitors of Androgen Biosynthesis
Second Generation
- SELECTIVE inhibitor
- does NOT inhibit CYP3A4
Estradiol
1) Inhibitors of Hypothalamic-Pituitary-Testes Signaling
Estrogenic Treatment
DES
Diethylsilbestrol
1) Inhibitors of Hypothalamic-Pituitary-Testes Signaling
Estrogenic Treatment
Leuprolide
1) Inhibitors of Hypothalamic-Pituitary-Testes Signaling
GnRH receptor agonists
D Leu
Goserelin
1) Inhibitors of Hypothalamic-Pituitary-Testes Signaling
GnRH receptor agonists
D Ser
Degarelix
1) Inhibitors of Hypothalamic-Pituitary-Testes Signaling
GnRH receptor agonists and antagonists
Relugolix
1) Inhibitors of Hypothalamic-Pituitary-Testes Signaling
GnRH receptor agonists and antagonists
Inhibitors of Hypothalamic-Pituitary-Testes Signaling
Ranking
1) GnRH Receptor Agonists or Antagonists: chemical castration
2) Orchiectomy: surgical castration
3) Estrogen Treatment
- will not bind AR & promote growth of tumor
- need v. high levels; nasty side effects
Castration Level
<50 ng/dL
GnRH Receptor Agonists
- reversible
- used clinically for infertility
Mechanism of action:
- distorts normal pulsatile signaling from hypothalamic GnRH thus desensitizing the pituitary to GnRH
- – overwhelms pituitary and shuts down LH & FSH
- painful with metastases
GnRH Receptor Antagonists
- reversible
- bind GnRH receptor and block gonadotropic secretion
Mechanism of Action: competitively and reversibly inhibit GnRH receptors in pituitary gland which blocks FSH, LH, and T release
Synthetic GnRH Agonists
> > t1/2 and binding affinity for GnRH receptor than GnRH
Advantages of GnRH ANTagonists over GnRH agonists
1) RAPID suppression of FSH, LH, and T
2) no microsurges
3) prolonged suppression of FSH, LH, and T
GnRH Antagonist Side Effects
- injection site reaction
- hot flashes
- fatigue
- weight gain
- hepatotoxicity
Abiraterone vs Ketoconazole at Adrenal Cortex
Ketoconazole: shuts down everything
- side effects: blocks cortisol and aldosterone synthesis too
- inhibits CYP3A4 actively in liver affecting drug metabolism
Abiraterone: inhibit in adrenal cortex - CYP17 - DHEA - Aldosterone ~ Cortisol
Inhibitors of DHT Biosynthesis
- inhibits 5-a-reductase
- target tissue: prostate, scalp
Used to treat:
- hair loss
- benign prostate hyperplasia
- prostate cancer
AR antagonists (aka Anti-androgens) First Generation
Flutamide
Bicalutamide
AR antagonists (aka Anti-androgens) Second Generation
Enzalutamide
Apalutamide
Darolutamide
Enzalutamide
nonsteroidal AR antagonist
- been around the longest
- approved for all stages of prostate cancer
- very expensive
1st & 2nd Generation AR Antagonists
- work by binding to AR and preventing binding of either
- – DHT
- – Testosterone
- Drugs inhibit
- – localization of AR to nucleus
- – ability of receptor to bind to DNA
- – ability to recruit co-activators
- – ability to regulate gene expression
1st vs 2nd AR Antagonists
AR Nuclear Import
- 1st: inhibits nuclear import
- 2nd: completely blocks AR transport into nucleus
- – if AR can’t get into nucleus: ALL STOP
1st vs 2nd AR Antagonists
AR Binding Dd
- 1st: 160
- 2nd: 25
- DHT: 5
Which 2nd Generation AR Antagonist has highest potency/shortest t1/2?
Darolutamide
Which 2nd AR Antagonists can cross brain/blood barrier?
Enzalutamide & Apalutamide
- why such significant CNS side effects
Prostate Cancer Treatment Paradigm
Advanced Castration Sensitive Prostate Cancer
Goal: lower serum testosterone to “castrate” levels (<50 ng/dL)
Treatment: Androgen Deprivation Therapy
#1: Chemical Castration (80%)
2) Surgical Castration (Orchiectomy)
3) Estrogen (last resort; nasty side effects)
Castrate Levels
Serum testosterone <50 ng/dL
Prostate Cancer Treatment Paradigm
Cancer Progression to Castrate Resistant Prostate Cancer
- increasing PSA levels & metastases
- introduce Secondary Hormonal Therapy
- Chemotherapy
- Immunotherapy
Secondary Hormonal Therapies
- 1st & 2nd Gen Anti-Androgen
- Androgen Inhibitors
- DHT Inhibitors
Buserelin
- inhibitor of hypothalamic-pituitary-testes signaling
- GnRH Receptor Agonist (increases GnRH released from hypothalamus to pituitary)
D-Ser
Testosterone Enanthate
Testosterone Ester
- esterification of C17 hydroxyl group
- Type A modification
- Intramuscular injection; every 2-3 weeks
Testosterone Cypionate
- testosterone ester
- esterification of C17 hydroxyl group
- type A modification